Pacer Advisors
JANX icon

Pacer Advisors’s Janux Therapeutics JANX Stock Holding History

Pacer Advisors’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14K Buy
+895
New +$13K ﹤0.01% 2310
2024
Q3 		– Sell
-439
Closed -$18.4K – 2626
2024
Q2 		$18.4K Buy
+439
New +$20.6K ﹤0.01% 3443

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Pacer Advisors's JANX Position: Q2 2026 in Review

Pacer Advisors opened a new position in Janux Therapeutics (JANX) in Q2 2026: 895 shares worth $14K. The stake represents ﹤0.01% of the portfolio and ranks #2310 among its holdings. This is a return to the name: Pacer Advisors previously reported a position in JANX as recently as Q2 2024.

Pacer Advisors first reported a position in JANX in Q2 2024 and has held it in 2 quarters since. The position peaked at $18.4K in Q2 2024. 198 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • Pacer Advisors held 895 shares of Janux Therapeutics worth $14K as of Q2 2026.
  • Janux Therapeutics was a new Pacer Advisors position in Q2 2026.
  • Janux Therapeutics made up ﹤0.01% of Pacer Advisors's portfolio in Q2 2026, its #2310 holding.
  • Pacer Advisors first reported a position in Janux Therapeutics in Q2 2024 and has held it in 2 quarters since.
  • Pacer Advisors's Janux Therapeutics position peaked at $18.4K in Q2 2024.
  • 198 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Pacer Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.